Arecor
Little Chesterford
About Arecor
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides. In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $41.8M
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2025)
- Ticker: lse:AREC
- Website: arecor.com
- Phone: +441223426060
Industries & Categories
Biopharma, Biotechnology, Education, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/arecor-67433 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.